A survey conducted in the early months of the pandemic revealed cancer survivors’ greatest concerns regarding their care, prognosis, and finances.
A team of international investigators deployed a survey to understand the needs of patients with EGFR-positive lung cancer community.
Oblato plans to evaluate OKN-007 for diffuse intrinsic pontine glioma in a phase 1/2 trial this year.
Cavrotolimod is a toll-like receptor 9 agonist that is designed to induce anticancer immune responses through proprietary spherical nucleic acid (SNA™) technology.
A team of researchers conducted a study to assess the impact of the COVID-19 pandemic on the initiation of clinical trials in oncology.
Whether inherited or acquired, bleeding disorders can cause significant pain, inconvenience, and stress in a person’s life. When patients think they or a loved one may have a bleeding disorder, what should they know?
A review of meta-analyses sought to grade the evidence related to associations between dietary factors and colorectal cancer risk.
Continued approval of the indication was contingent upon establishing the superiority of Keytruda as determined by overall survival.
The approval was based on data from 3 randomized, placebo-controlled trials that included 245 adults with ES-SCLC.
A team of investigators sought to determine outcomes from combination low-dose carboplatin plus nab-paclitaxel with concurrent radiotherapy among elderly patients with advanced non-small cell lung cancer.
A retrospective study of electronic health records sought to determine the effect of presence of diabetes on long-term outcomes for colorectal cancer survivors.
The number of genes tested for ovarian and breast cancer has grown, but most patients do not undergo testing, and variant-of-unknown-significance results are common, especially among minority populations.
Although patient-reported outcomes measures were similar with lorlatinib and crizotinib in non-small cell lung cancer, more patients reported improvement in symptoms with lorlatinib.
Study findings demonstrate the rates of immune-related adverse events and flares of the underlying disorders in this patient population.
The EUA was based on data from the randomized, double-blind, placebo-controlled ENSEMBLE trial.